Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, O'Byrne PM.
Gauvreau GM, et al.
J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7.
J Allergy Clin Immunol. 2016.
PMID: 27185571
Clinical Trial.